Scarica l'app Stockscreener
72.70
4.33%
3.02
Dopo l'orario di chiusura:
72.70
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
IONS: HC Wainwright & Co. Raises Price Target to $120 | IONS Sto - GuruFocus
Stifel raises Ionis Pharmaceuticals price target on drug pricing By Investing.com - Investing.com India
IONS: Needham Raises Price Target for Ionis Pharmaceuticals | IO - GuruFocus
Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright - MarketBeat
Wolfe Research reiterates Ionis stock rating on pricing strategy - Investing.com
Patterns Watch: Why is Ionis Pharmaceuticals Inc stock going upAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - The Globe and Mail
Aug Big Picture: Does Ionis Pharmaceuticals Inc outperform in volatile marketsSwing Trade & Weekly Chart Analysis and Guides - baoquankhu1.vn
When Insider Selling Is a Good Thing: 2 Stocks to Watch - Investing.com
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
FDA accepts zilganersen application for Alexander disease review By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (IONS) Gains FDA Priority Review for Zilga - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $412,477.64 in Stock - MarketBeat
Ionis Pharma EVP Schneider sells $412k in shares By Investing.com - Investing.com South Africa
Ionis Pharma EVP Schneider sells $412k in shares - Investing.com
Ionis gains priority review for zilganersen for Alexander disease - MSN
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - BioSpace
FDA Prioritizes Review of Ionis Pharmaceuticals' Drug for Alexan - GuruFocus
Ionis Pharmaceuticals, Inc. recently announced that its New Drug Application (NDA) for Zilganersen, a new treatment developed for Alexander disease (AxD), has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA). - Bitget
FDA accepts zilganersen application for Alexander disease review - Investing.com
Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Ionis Board Shakeup And Valuation Gap Draw Investor Attention - Yahoo Finance
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative (NASDAQ:IONS) - Seeking Alpha
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
Affiliate files Form 144 to sell shares — IONS (NASDAQ: IONS) - Stock Titan
Why Ionis Pharmaceuticals’ (IONS) 2026 catalyst pipeline supported Leerink’s higher target - MSN
Hudson Bay Capital Management LP Decreases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Groupama Asset Managment - MarketBeat
Insider Sell: Elizabeth Hougen Sells 225,220 Shares of Ionis Pha - GuruFocus
Did Ionis Pharmaceuticals' (IONS) Board Refresh and Return of Peter Reikes Just Shift Its Investment Narrative? - simplywall.st
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 215,048 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $744,692.12 in Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ: IONS) CFO sells 225,220 shares after option exercises - Stock Titan
Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Airsculpt Technologies (AIRS) and NRX Pharmaceuticals (NRXP) - The Globe and Mail
BlueCrest Capital Management Ltd Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Alpine Global Management LLC Acquires 30,463 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Retail Trends: Can Ionis Pharmaceuticals Inc outperform in the next rally2026 Rallies & Stock Market Timing Techniques - baoquankhu1.vn
Bamco Inc. NY Makes New $1.64 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - National Today
Goldman Sachs Upgrades Ionis Pharmaceuticals (IONS) - MSN
IONS (IONS) Form 144 notices proposed resale of 225,200 shares - Stock Titan
Ionis Pharmaceuticals (IONS) Among Most Oversold Healthcare Stocks - GuruFocus
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat
BlueCrest Capital Management Ltd Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Cinctive Capital Management LP Invests $11.37 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Boone Capital Management LLC Takes $27.34 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Baker BROS. Advisors LP Makes New $37.08 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Stock (ISIN: US46120E6023) Faces Pressure Amid Biotech Volatility - AD HOC NEWS
Algert Global LLC Grows Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN
IONS SEC FilingsIonis Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Atika Capital Management Invests $1.41M in Ionis Pharmaceuticals - National Today
Connor Clark & Lunn Investment Management Ltd. Raises Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Atika Capital Management LLC Invests $1.41 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Insider Sell: Brett Monia Sells 160,773 Shares of Ionis Pharmace - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Sells $9,525,584.00 in Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia Sells 34,103 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Patrick O'neil Sells 10,148 Shares - MarketBeat
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):